Market closed
Revance Therapeutics/$RVNC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Revance Therapeutics
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
Ticker
$RVNC
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
597
Website
RVNC Metrics
BasicAdvanced
$319M
Market cap
-
P/E ratio
-$1.91
EPS
0.95
Beta
-
Dividend rate
Price and volume
Market cap
$319M
Beta
0.95
52-week high
$9.75
52-week low
$2.30
Average daily volume
3M
Financial strength
Current ratio
4.119
Quick ratio
2.902
Long term debt to equity
-279.755
Total debt to equity
-296.539
Interest coverage (TTM)
-8.40%
Management effectiveness
Return on assets (TTM)
-24.36%
Return on equity (TTM)
225.10%
Valuation
Price to revenue (TTM)
1.145
Price to book
-1.96
Price to tangible book (TTM)
-1.87
Price to free cash flow (TTM)
-1.509
Growth
Revenue change (TTM)
25.82%
Earnings per share change (TTM)
-61.84%
3-year revenue growth (CAGR)
59.79%
3-year earnings per share growth (CAGR)
-24.73%
What the Analysts think about RVNC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Revance Therapeutics stock.
RVNC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RVNC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RVNC News
AllArticlesVideos
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·7 hours ago
Revance agrees to lower-priced buyout offer by Crown Laboratories
Reuters·3 days ago
Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Revance Therapeutics stock?
Revance Therapeutics (RVNC) has a market cap of $319M as of December 12, 2024.
What is the P/E ratio for Revance Therapeutics stock?
The price to earnings (P/E) ratio for Revance Therapeutics (RVNC) stock is 0 as of December 12, 2024.
Does Revance Therapeutics stock pay dividends?
No, Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Revance Therapeutics dividend payment date?
Revance Therapeutics (RVNC) stock does not pay dividends to its shareholders.
What is the beta indicator for Revance Therapeutics?
Revance Therapeutics (RVNC) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.